Junshi Biosciences and Coherus BioSciences announce initiation of rolling submission of BLA for toripalimab to the U.S. FDA for the treatment of nasopharyngeal carcinoma

Junshi Biosciences

3 March 2021 - BLA submitted with FDA’s breakthrough therapy designation.

Shanghai Junshi Biosciences and Coherus Biosciences announced today the initiation of the rolling submission of the biologics license application for toripalimab to the U.S. FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma.

Read Junshi Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Dossier